Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine • Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise • and more…| Psychedelic Alpha
AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vouchers • California’s Newsom Signs AB 1103, Easing Review Bottleneck for Psychedelic Studies • Funding Lags Sentiment…. Or Does It? and more…| Psychedelic Alpha